Maximum androgen blockade

Maximum androgen blockade (MAB) or complete or combined androgen blockade (CAB) is a medical treatment involving the combination of both androgen receptor (AR) antagonism and inhibition or suppression of androgen production to attain maximal effectiveness in androgen deprivation therapy.[1] An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) GnRH analogue such as leuprorelin or cetrorelix.[1] Cyproterone acetate and galeterone are examples of MAB that combine both mechanisms into a single drug. MAB was developed for and is employed in the treatment of prostate cancer.[1]

References

  1. 1 2 3 "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials". The Lancet 355 (9214): 1491–1498. 2000. doi:10.1016/S0140-6736(00)02163-2. ISSN 0140-6736.


This article is issued from Wikipedia - version of the Wednesday, March 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.